EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats

Maaly A Abd Elmaaboud, Remon S Estfanous, Aliaa Atef, Ahmed M Kabel iD, Khalid A Alnemari, Tamer M Naguib iD, Shuruq E Alsufyani iD, Hany W Darwish, Hany H Arab iD

Pharmaceuticals · 27.09.2023 · 16 (10) · 1370

DOI: 10.3390/ph16101370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 27.09.2023. Verfasst von Maaly A Abd Elmaaboud und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta 31527, Egypt. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University, Riyadh, Saudi Arabia, King Saud University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is the most common form of neurodegenerative disorders worldwide. Its pathologic features include massive neuroinflammation with abnormal deposition of β-amyloid peptide in the cerebral tissues leading to degeneration of the brain neurons. Adverse effects associated with the traditional drugs used for the treatment of this pathological condition have directed the research efforts towards searching for alternative effective agents with minimal adverse effects. The aim of this study was to elucidate the potential ameliorative effects of dapagliflozin and/or hesperidin on Alzheimer’s disease (AD) induced by lipopolysaccharide (LPS) injection in rats. In a rodent model of AD, the effect of dapagliflozin with or without hesperidin on the biochemical parameters and the behavioral tests as well as the histopathological parameters was determined. Each of dapagliflozin and hesperidin restored the behavioral tests to the reference values, augmented the antioxidant defense mechanisms, ameliorated the neuronal inflammatory responses, combatted the changes in Toll-like receptor-4 (TLR-4)/High-mobility group box 1 (HMGB1) protein signaling and receptors of advanced glycation end products (RAGE) levels, and restored the balance between the apoptotic signals and autophagy in the hippocampal tissues. Additionally, both agents exhibited an outstanding ability to combat LPS-induced perturbations in the histopathological and electron microscopic image of the brain tissues. These favorable effects were significantly encountered in the group treated with dapagliflozin/hesperidin combination when compared versus animals treated with either dapagliflozin or hesperidin. In conclusion, inhibition of the hippocampal HMGB1/TLR4/RAGE signaling, the pro-inflammatory axis, and apoptosis alongside augmentation of the antioxidant defenses and autophagy can be regarded as beneficial effects by which dapagliflozin/hesperidin combination may combat LPS-triggered AD.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseapoptosisautophagydapagliflozinhesperidininflammatory cascadelipopolysaccharideoxidative stressrats

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta 31527, Egypt.
  • Anatomy and Embryology Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt.
  • Department of Pathology, Faculty of Medicine, Tanta University, Tanta 31527, Egypt.
  • Taif Medical Center, Taif 26526, Saudi Arabia.
  • Anesthesia and ICU Department, Faculty of Medicine, Tanta University, Tanta 31527, Egypt.
  • Department of Pharmacology and Toxicology, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.

ORCID-Profile: Ahmed M Kabel, Tamer M Naguib, Shuruq E Alsufyani, Hany H Arab

Förderung

  • King Saud University, Riyadh, Saudi Arabia
  • King Saud University

Zitieren

APA

Abd Elmaaboud, M. A., Estfanous, R. S., Atef, A., Kabel, A. M., Alnemari, K. A., Naguib, T. M., Alsufyani, S. E., Darwish, H. W., & Arab, H. H. (2023). Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats. Pharmaceuticals, 16(10), 1370. https://doi.org/10.3390/ph16101370

Vancouver

Abd Elmaaboud MA, Estfanous RS, Atef A, Kabel AM, Alnemari KA, Naguib TM, et al. Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats. Pharmaceuticals. 2023;16(10):1370. doi:10.3390/ph16101370

BibTeX
@article{AbdElmaaboud2023,
  author = {Abd Elmaaboud, Maaly A and Estfanous, Remon S and Atef, Aliaa and Kabel, Ahmed M and Alnemari, Khalid A and Naguib, Tamer M and Alsufyani, Shuruq E and Darwish, Hany W and Arab, Hany H},
  title = {Dapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer’s Disease in Rats},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {10},
  pages = {1370},
  doi = {10.3390/ph16101370}
}
Kostenlos starten →